GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

GSK (NYSE:GSK) announced Tuesday that Arexvy, a Phase 3 trial for its FDA-approved vaccine against Respiratory Syncytial ...

GSK shared new Phase III data on Arexvy, its RSV vaccine, at the 2024 CHEST annual meeting. Results show a single dose of ...

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST ...

Meanwhile, demand for vaccines targeting respiratory syncytial virus are down in the U.S. Also, if you are uncertain about whether you might have covid or the flu, the newly approved at-home Healgen ...

GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting: London, UK Wednesday, October 9, 2024, 14:0 ...

GSK's Arexvy RSV vaccine demonstrated 43.3% effectiveness in preventing severe illness in its third trial season, following 94.1% effectiveness initially and 64.2% in the second year. The vaccine, one ...

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...

GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV disease over three ...